SHARE:  

COVID-19 Rebound After Paxlovid

May 24, 2022

Today, the Centers for Disease Control and Prevention released a Health Advisory with considerations around the phenomena of rebound, after treatment of patients with mild to moderate COVID-19, with Paxlovid (nirmatrelvir tablets; ritonavir tablets).

Download Health Advisory

Additional Recommendations

For questions or concerns, providers can contact the OCHCA Communicable Disease Control Division at 714-834-8180.